PHARMACEUTICALS
Humanwell
Wuhan, Hubei, China · Group heritage to 1954 · Yichang Humanwell established 2001
Anaesthesia and analgesia chemistry, at hospital-grade quality.
Controlled-substance manufacturing is a different discipline from general API production. The regulatory perimeter, the security requirements, the licensing, and the quality expectations are all set at a higher level, and very few manufacturers hold the authorisations to operate inside it. Humanwell has been a nationally designated anaesthetics manufacturer in China since 1970.
Yichang Humanwell, the group's anaesthetics business, operates finished dosage and API production lines certified by the US Food and Drug Administration and to EU GMP. Its portfolio covers the principal molecules used in general anaesthesia, procedural sedation, and acute pain management, alongside two innovative sedation agents developed in-house.
- Cosmetics & Personal Care
Over 400 mineral salts and more than 7,000 specifications. The specification count is the more meaningful number: it is the measure of how far a grade can be tailored.
ABOUT THIS PRINCIPAL
A controlled-substance manufacturer with an innovation pipeline.
Humanwell Healthcare Group traces its pharmaceutical operations to the Hubei Yiyao Group, established in 1954. Yichang Humanwell was formed as a distinct entity in 2001 and became the country's largest government-designated developer and manufacturer of anaesthetic drugs. It holds more than seventy patents and was the first pharmaceutical company in Hubei province to have both finished dosage and API production lines certified by the US FDA.
The research base is unusually large for a supplier in this category: more than 2,000 R&D personnel including over 120 PhDs, with research centres in China and the United States. That capability has produced approved innovative agents rather than generics alone. Remimazolam besylate for injection was the first new chemical entity of its class approved in Hubei province and broke a roughly thirty-year gap in newly listed sedation agents. Fospropofol disodium for injection followed as the first propofol prodrug approved in China.
Internationally, the group acquired Paion, a German specialty pharmaceutical company based in Aachen focused on hospital sedation, anaesthesia and critical care, in 2024, and operates Epic Pharma in the United States. Commercial infrastructure in China reaches around 10,000 hospitals and 30,000 pharmacies.
The combination is rare: narcotic API capacity, sterile injectable finished dose capability, and an approved innovative sedation pipeline, inside one certified organisation.
ADCHEM works with Humanwell on the regulated introduction of anaesthesia and analgesia products, supported by our own regulatory affairs capability. Controlled-substance products are supplied strictly within the licensing framework of the destination market.
FEATURED TECHNOLOGY
Four capabilities that define the operation.
The technical case for Humanwell rests on licensed capability and vertical control rather than on a single molecule.
LICENSED MANUFACTURE
Narcotic API production
Seven dedicated narcotic API production lines, operated under national designation and certified to Chinese GMP, with FDA and EU GMP certification on the relevant lines. This licensing perimeter is the barrier to entry in the category.
INTEGRATION
API to sterile finished dose
Twenty-six finished dosage production lines allow the group to supply either the API or the finished injectable from the same quality system, which shortens qualification for customers taking both.
INNOVATION
In-house new chemical entities
Remimazolam besylate and fospropofol disodium were both developed and approved in-house, evidence of formulation and clinical development capability rather than process chemistry alone.
REGULATORY REACH
International filings
Drug Master Files, Certificates of Suitability and ANDA approvals support supply into regulated markets, with more than 80 products exported to over 70 countries.
Portfolio
The Humanwell portfolio.
Anaesthesia, sedation and analgesia products, supplied as APIs and finished dosage forms. All controlled-substance products are supplied only within the licensing framework of the destination market.
Remifentanil
What it is
Ultra short-acting synthetic opioid analgesic; DMF and CEP filed
Primary Use
Balanced general anaesthesia, procedural analgesia, intensive care sedation
Fentanyl
What it is
Synthetic opioid analgesic; CEP filed
Primary Use
General anaesthesia and severe acute pain management
Fentanyl citrate
What it is
Citrate salt of fentanyl; CEP filed
Primary Use
Injectable anaesthesia and analgesia formats
Hydromorphone hydrochloride
What it is
Semi-synthetic opioid analgesic; CEP filed
Primary Use
Severe pain management, including patient-controlled analgesia
Midazolam
What it is
Short-acting benzodiazepine; CEP filed
Primary Use
Procedural sedation, premedication, induction of anaesthesia, ICU sedation
Tapentadol
What it is
Centrally acting analgesic with a dual mechanism; CEP filed
Primary Use
Moderate to severe acute and chronic pain
Remimazolam besylate
What it is
Ultra short-acting benzodiazepine sedative and anaesthetic, developed in-house; commercialised in Europe as Byfavo through Paion
Primary Use
Procedural sedation and general anaesthesia where rapid, controllable offset is required
Fospropofol disodium
What it is
Water-soluble prodrug of propofol, the first approved in China
Primary Use
Intravenous anaesthesia and sedation with a modified pharmacokinetic profile
Additional controlled-substance APIs
What it is
Further anaesthesia, sedation and analgesia molecules across the seven narcotic API lines
Primary Use
Available on request, subject to import licensing in the destination market
Finished dosage forms
What it is
Sterile injectables and other formats produced across 26 finished dosage lines
Primary Use
Hospital supply, tender participation, and licensed in-market registration
APPLICATION AREAS
Where Humanwell products are used.
General anaesthesia
Induction and maintenance agents covering both the opioid analgesic and the sedative-hypnotic components of a balanced technique.
REMIFENTANIL
FENTANYL
FOSPROPOFOL
Procedural sedation
Short-acting agents where predictable offset governs turnover in endoscopy, day surgery and diagnostic procedures.
MIDAZOLAM
REMIMAZOLAM
Acute pain management
Post-operative and trauma analgesia, including formats suited to patient-controlled administration.
HYDROMORPHONE
FENTANYL
Chronic pain
Centrally acting analgesia for moderate to severe chronic pain where a dual mechanism is clinically preferred.
TAPENTADOL
Intensive care
Sedation agents for mechanically ventilated and critically ill patients, where controllability and accumulation profile matter.
REMIMAZOLAM
MIDAZOLAM
Hospital tender supply
Finished dosage supply into hospital procurement, supported by the group's regulatory filings in the relevant markets.
FINISHED DOSAGE
DOCUMENTATION TO BE HELD
Regulatory documentation that supports the filing, not just the purchase order.
Humanwell products are supplied with the documentation required for regulatory submission, supplier qualification, and controlled-substance import licensing. Because much of the portfolio is scheduled, supply is conditional on the correct import authorisation and manufacturing licence being held in the destination market, and ADCHEM will not initiate a shipment before that documentation is in place.
Product and quality
- Product specification sheet
- Certificate of Analysis (CoA), batch specific
- Safety Data Sheet (SDS / MSDS)
- Compendial compliance statement against USP/NF, Ph. Eur., JP or BP as applicable
- Analytical methods and method validation summary
- Physical characterisation data: particle size distribution, bulk and tapped density, loss on drying
- Stability data with retest period or shelf life justification
Regulatory filings
- Drug Master File number with Letter of Access
- Certificate of Suitability (CEP / COS) where filed
- Written Confirmation for API import into the European Union
- Manufacturing licence and site registration details
- Open part documentation for inclusion in the applicant’s submission
- Regulatory support commitment for market registration and variations
GMP and quality system
- GMP certificate for the manufacturing site
- Excipient GMP statement aligned to IPEC-PQG or EXCiPACT, for excipient grades
- ISO 9001 certificate
- Quality Agreement
- Change control and prior notification commitment
- Most recent regulatory inspection outcome summary
- Completed supplier questionnaire or audit report
Impurities and biological safety
- Elemental impurities risk assessment (ICH Q3D)
- Residual solvents data (ICH Q3C)
- Genotoxic and mutagenic impurity assessment (ICH M7)
- Nitrosamine risk evaluation
- Related substances and impurity profile with named and characterised impurities
- Microbiological limits and bioburden data
- Bacterial endotoxin data where the grade or route requires it
Origin and declarations
- Manufacturing process flow chart and route of synthesis summary
- Starting material identity and origin statement
- TSE / BSE-free declaration
- GMO-free statement
- Allergen statement
- Residual antibiotic and cross-contamination control statement
- Latex-free and melamine-free statements
- Country of origin declaration
- Halal and Kosher certificates where required by the market
- Packaging and container closure specification
WORKING WITH ADCHEM
What ADCHEM adds to the Humanwell relationship.
LICENSING-FIRST
Controlled-substance import navigation
Scheduled products require import permits, quota allocation and licensed handling. We map the requirement in the destination market before the commercial discussion, not after.
SUBMISSION-READY
Registration and dossier support
CEP and DMF references, stability data, and manufacturing evidence assembled for in-market registration submissions.
SINGLE-SOURCE QUALIFICATION
API or finished dose, one qualification
Where a customer needs both the API and the finished injectable, sourcing from one certified quality system materially shortens the qualification path.
COMPLIANT HANDLING
Cold chain and secure logistics
Handling, storage and chain-of-custody arrangements appropriate to scheduled and temperature-sensitive product.
On this page
QUICK FACTS
GROUP HEADQUARTERS
Wuhan, Hubei, China
GROUP HERITAGE
Predecessor Hubei Yiyao Group, established 1954
ANAESTHETICS BUSINESS
Yichang Humanwell Pharmaceutical Co., Ltd., established 2001
DESIGNATION
Nationally designated anaesthetics manufacturer in China since 1970
CAPACITY
26 finished dosage production lines and 7 narcotic API production lines
REGULATORY
Finished dosage and API lines certified by US FDA and to EU GMP
INTERNATIONAL FOOTPRINT
More than 80 products exported to over 70 countries; European presence through Paion, acquired 2024
Certifications
COSMOS Certified grades
Ecocert Certified
Vegan-aligned lines
Halal-aligned grades
Licensed capability, certified lines, and a real pipeline.
Three ways to start: a technical enquiry, a regulatory documentation request, or a conversation with a specialist who understands the licensing position in your market.
Request a Sample
Any product in the portfolio
Download a TDS
Full technical library
Talk to Our Specialist
Someone who knows the chemistry first
OTHER PRINCIPALS IN THIS SEGMENT
Pharmaceuticals
Shin-Etsu
·Dr. Paul Lohmann
Fuji Chemicals
Gangwal
Nippon Soda
Beneo
Seppic
Vanderbilt Minerals